

DESCRIPTION

ASSAY METHOD FOR IDENTIFYING DRUG CANDIDATE

Technical Field

The present invention relates to a method of identifying
5 a drug candidate capable of removing peptide, oligopeptide,
polypeptide or protein from fibril or aggregate.

Background Art

Senile plaque containing amyloid β (hereinafter to be
also referred to as $A\beta$) is one of the pathological features of
10 Alzheimer's disease.

Reduction of $A\beta$ is considered to be a primary therapeutic
target.

There are reports on amyloid clearance after immunization
with anti- $A\beta$ antibodies.

15 Recent data reveal that the antibodies may act as
peripheral sink for $A\beta$ to alter the periphery/brain dynamics.

The factual disappearance of senile plaque indicates that
the $A\beta$ aggregation process is reversible.

However, there are no evidence of dissolution of soluble
20 $A\beta$ from aggregated $A\beta$.

Here, the present inventors have developed a sink-like $A\beta$
assay for the analysis of *in vitro* transfer (replacement) of
fibril to the supernatant following centrifugation, by which
not only dissolution of soluble $A\beta$ from aggregated $A\beta$ but also
25 promotion of the dissolution of $A\beta$ by ultrasonication are
indicated.

A compound or ultrasonication that promotes dissolution
of $A\beta$ in the *in vitro* sink-like $A\beta$ assay may become a
potential alternative to the treatment of Alzheimer's disease.

30 Alzheimer's disease (AD) is a neurodegenerative disease
characterized by the presence of senile plaques in brain.

$A\beta$ peptide consisting of 40-42 amino acids is the main
component of senile plaque.

The inheritable character of this disease is related to

the mutation of amyloid precursor protein (APP) and presenilin gene.

The mutation in these genes relating to the disease increases production of A β (1-42) predominantly present in the
5 senile plaques.

Recently, immunization of mutant APP transgenic mouse with A β has been shown to be effective for suppressing plaque deposition (Schenk, Barbour et al. 1999).

Both plaques and neuritic lesions were reversible after
10 administration of a single dose of A β antibody (Lombardo, Stern et al. 2003).

In addition to the A β antibody, a peripheral treatment with a pharmaceutical agent having high affinity for A β (gelsolin or GM1) reduced the level of A β in the brain
15 (Matsuoka, Saito et al. 2003).

It has been proposed that generation of a peripheral sink mechanism via administration of antibodies is useful for treating a number of disorders characterized by the abnormal protein accumulation in an extracellular space (DeMattos,
20 Bales et al. 2001).

The A β aggregation process has been sufficiently studied *in vitro*.

However, the reverse phenomenon wherein A β is dissolved from aggregated A β has not been studied yet.

25 In this study, we developed a novel *in vitro* sink-like A β assay to study dissolution of A β from aggregated A β .

We found that soluble A β dissolved from aggregated A β .

In addition, ultrasonication promoted dissolution of A β .

The compound and/or ultrasonication that promoted
30 dissolution of A β in the *in vitro* sink-like A β assay may become an alternative for the treatment of Alzheimer's disease.

WO94/10569 (JP-A-8-502587) discloses a method for diagnosing or monitoring a β -amyloid peptide (hereinafter to be also referred to as β AP)-related condition in a patient, said

method comprising: measuring the amount of soluble β AP or β AP fragments in a patient sample; comparing the measured amount with a predetermined amount of β AP or β AP fragments; and assessing patient status based on the difference between the
5 measured and predetermined β AP or β AP fragment amounts (claim 23).

WO00/26238 (JP-A-2002-531065) discloses a method of identifying an agent which is capable of preventing, reducing and/or reversing the conversion of prion protein to a β -form,
10 the method comprising: providing a sample of a prion protein and comparing the amount of the β -form qualitatively or quantitatively in the presence and absence of a test agent (claim 50).

WO00/43791 (JP-A-2002-540383) discloses a method
15 comprising: forming a solution containing a species capable of binding neurodegenerative disease aggregate-forming or fibril-forming species and one of a sample suspected of containing neurodegenerative disease aggregate-forming or fibril-forming species for a drug candidate for inhibition of
20 neurodegenerative disease aggregate or fibril-formation; and, without transferring any components into the solution or removing the solution from its container, detecting aggregation in the solution characteristic of neurodegenerative diseases (claim 172).

25 For evaluation of a number of test compounds, however, these prior arts are not easy, not quick, not highly reliable or not economical methods.

Disclosure of the Invention

The present inventors have conducted intensive studies in
30 an attempt to establish a method of identifying a drug candidate usable for the treatment of a disease caused by aggregation of peptide, oligopeptide, polypeptide or protein. They have found that the $A\beta$ aggregation process is reversible, and established a method capable of identifying a drug

candidate capable of removing peptide, oligopeptide, polypeptide or protein from fibril or aggregate, by measuring, in the presence of a test compound, the concentration of a soluble peptide, a soluble oligopeptide, a soluble polypeptide
5 or a soluble protein in an equilibrium state in a solvent.

Accordingly, the present invention provides the following.

(1) A method of identifying a drug candidate capable of removing peptide, oligopeptide, polypeptide or protein from
10 fibril or aggregate, which comprises measuring, in the presence of a test compound, the concentration of a soluble peptide, a soluble oligopeptide, a soluble polypeptide or a soluble protein in an equilibrium state in a solvent.

(2) The method of the above-mentioned (1), wherein the drug
15 candidate is used for the treatment of a disease caused by the aggregation of peptide, oligopeptide, polypeptide or protein.

(3) The method of the above-mentioned (1) or (2), wherein the disease is selected from the group consisting of Alzheimer's disease (AD), Parkinson's syndrome (PD), Huntington chorea,
20 prion disease, Down's syndrome, Lewy body dementia, multiple system atrophy, Creutzfeldt-Jakob disease, Gerstmann-Sträussler syndrome, mad cow disease, spinobulbar muscular atrophy, spinocerebellar ataxia (SCA), dentatorubral-pallidoluysian atrophy (DRPLA), familial amyotrophic lateral
25 sclerosis retinitis, FTDP-17 (frontotemporal dementia and parkinsonisms linked to chromosome 17), progressive supranuclear palsy, corticobasal degeneration, Pick disease, familial British dementia and familial dementia accompanying neuroserpin inclusion bodies.

30 (4) The method of any of the above-mentioned (1) to (3), wherein the fibril or aggregate was formed *in vitro*.

(5) The method of any of the above-mentioned (1) to (4), wherein the equilibrium state is achieved under ultrasonication.

- (6) The method of any of the above-mentioned (1) to (5), wherein the ultrasonication is substantially unaccompanied by heat generation.
- (7) The method of any of the above-mentioned (1) to (6),
5 wherein the ultrasonication conditions include 5 repeats of a 30 second ultrasonication at 1 MHz, 2 W/cm², duty ratio 20% with a 10 second pause.
- (8) A method of identifying a drug candidate capable of removing β -amyloid (A β) from fibril or aggregate formed in
10 vitro, which comprises measuring, in the presence of a test compound, the concentration of soluble β -amyloid (A β) in an equilibrium state in a solvent.
- (9) The method of the above-mentioned (8), wherein the fibril or aggregate consists of A β (1-40).
- 15 (10) The method of the above-mentioned (8), wherein the fibril or aggregate consists of A β (1-42).
- (11) The method of any of the above-mentioned (8) to (10), wherein the equilibrium state is achieved under ultrasonication.
- 20 (12) The method of any of the above-mentioned (8) to (11), wherein the ultrasonication is substantially unaccompanied by heat generation.
- (13) The method of any of the above-mentioned (8) to (12), wherein the ultrasonication conditions include 5 repeats of a
25 30 second ultrasonication at 1 MHz, 2 W/cm², duty ratio 20% with a 10 second pause.
- (14) A treatment method of a disease caused by aggregation of peptide, oligopeptide, polypeptide or protein, which comprises application of ultrasonication to a patient.
- 30 (15) The method of the above-mentioned (14), wherein the disease is selected from the group consisting of Alzheimer's disease, Parkinson's syndrome, Huntington chorea, prion disease, Down's syndrome, Lewy body dementia, multiple system atrophy, Creutzfeldt-Jakob disease, Gerstmann-Sträussler

syndrome, mad cow disease, spinobulbar muscular atrophy, spinocerebellar ataxia (SCA), dentatorubral-pallidoluysian atrophy (DRPLA), familial amyotrophic lateral sclerosis retinitis, FTDP-17, progressive supranuclear palsy,
5 corticobasal degeneration, Pick disease, familial British dementia and familial dementia accompanying neuroserpin inclusion bodies.

(16) A dissolution promoter for removing peptide, oligopeptide, polypeptide or protein from fibril or aggregate,
10 which comprises, as an active ingredient, the compound obtained by the method described in any of the above-mentioned (1) to (13).

(17) A dissolution promoter for removing peptide, oligopeptide, polypeptide or protein from fibril or aggregate,
15 which comprises, as an active ingredient, at least one selected from the group consisting of ferric dehydroporphyrin IX, amphotericin B, myricetin, tannic acid, curcumin, azure B and basic blue 41.

(18) A dissolution method comprising dissolving peptide,
20 oligopeptide, polypeptide or protein from fibril or aggregate, by the use of the compound obtained by the method described in any of the above-mentioned (1) to (13).

(19) Use of the compound obtained by the method described in any of the above-mentioned (1) to (13) for removing peptide,
25 oligopeptide, polypeptide or protein from fibril or aggregate.

(20) An apparatus for treating a disease caused by the aggregation of peptide, oligopeptide, polypeptide or protein, which comprises a means for ultrasonication of an affected part to remove peptide, oligopeptide, polypeptide or protein from
30 fibril or aggregate.

(21) A method of identifying a drug candidate capable of removing peptide, oligopeptide, polypeptide or protein from fibril or aggregate, which comprises measuring, in the presence of a test compound, the concentration of the soluble

peptide, soluble oligopeptide, soluble polypeptide or soluble protein dissolved from fibril or aggregate in a solvent.

Brief Description of the Drawings

Fig. 1 shows experimental procedures of *in vitro* sink-
5 like A β assay.

Fig. 2 shows dissolution of soluble A β from aggregated A β , as a result of sandwich ELISA for soluble A β (1-40) and A β (1-42).

Fig. 3 shows the results of mass analysis of dissolved A β
10 (1-40) and A β (1-42).

Fig. 4 shows the results of Western blot analysis of dissolved A β (1-40).

Fig. 5 shows SEC analysis charts of dissolved A β (1-40), which show promoted dissolution of A β by ultrasonication.

15 Fig. 6 shows experimental procedures for ultrasonication.

Fig. 7 shows the results of sandwich ELISA of dissolved A β (1-40).

Fig. 8 shows SEC analysis charts of fibrillization and oligomerization of A β (1-42).

20 Fig. 9 is a schematic showing of the *in vitro* sink-like A β assay.

Fig. 10 shows the results of Example 2.

Detailed Description of the Invention

The present invention is explained in detail in the
25 following.

<Identification method of drug candidates>

The present invention provides a method of identifying a drug candidate capable of removing peptide, oligopeptide, polypeptide or protein from fibril or aggregate, which
30 comprises measuring, in the presence of a test compound, the concentration of a soluble peptide, a soluble oligopeptide, a soluble polypeptide or a soluble protein in an equilibrium state in a solvent.

In the step of the identification method of the present

invention, the concentration of a soluble peptide, a soluble oligopeptide, a soluble polypeptide or a soluble protein in an equilibrium state in a solvent is measured in the presence of a test compound.

5 The test compound may be any known compound or novel compound and, for example, nucleic acid, carbohydrates, lipid, protein, peptide, organic low-molecular-weight compound, compound library prepared using combinatorial chemistry techniques, random peptide library prepared using solid phase
10 synthesis or phage display method, natural components derived from microorganism, plants, animals, marine animals etc., and the like can be mentioned. Alternatively, the test compound may be one actually used for the treatment of a disease caused by aggregation of peptide, oligopeptide, polypeptide or
15 protein.

 The above-mentioned soluble peptide, oligopeptide, polypeptide and protein are not particularly limited as long as their aggregation can cause an adverse effect, and eventually a disease and, for example, A β , prion protein,
20 polyglutamine, α synuclein, tau, superoxide dismutase-1 (SOD1), neuroserpin, amyloid precursor protein (APP) and the like can be mentioned.

 A β is a main component constituting senile plaque, which is one of the major neuropathological changes in Alzheimer's
25 disease, and produced by cleavage of amyloid precursor protein (APP) with two kinds of (β - and γ -) secretases. The major molecule species includes A β (1-40) (SEQ ID NO: 1) consisting of 40 amino acid residues and A β (1-42) (SEQ ID NO: 2) longer by 2 residues in the C-terminal side.

30 The aggregation or accumulation of A β is considered to cause diseases such as Alzheimer's disease, Down's syndrome and the like, and the accumulation sites thereof are senile plaque and cerebrovascular amyloid. Aggregation or accumulation of prion protein is considered to cause diseases

such as Creutzfeldt-Jakob disease, Gerstmann-Sträussler syndrome, mad cow disease and the like, and the accumulation sites thereof are synapse, nerve cell and Kuru plaque amyloid. The aggregation or accumulation of polyglutamine is considered
5 to cause diseases such as spinobulbar muscular atrophy, spinocerebellar ataxia (SCA), dentatorubral-pallidoluysian atrophy (DRPLA), Huntington chorea and the like, and the accumulation sites thereof are neuronal intranuclear inclusion bodies. The aggregation or accumulation of α -synuclein is
10 considered to cause diseases such as Parkinson's syndrome, Lewy body dementia, multiple system atrophy and the like, and the accumulation sites thereof are Lewy body (intraneuronal) and oligodendrocyte (GCI). The aggregation or accumulation of tau is considered to cause diseases such as Alzheimer's
15 disease, FTDP-17, progressive supranuclear palsy, corticobasal degeneration, Pick disease and the like, and the accumulation sites thereof are neurofibrillary tangle, glial inclusion bodies and Pick body. The aggregation or accumulation of superoxide dismutase-1 is considered to cause diseases such as
20 familial amyotrophic lateral sclerosis retinitis and the like, and the accumulation sites thereof are Lewy body-like inclusion bodies. The aggregation or accumulation of neuroserpin is considered to cause diseases such as familial dementia accompanying neuroserpin inclusion bodies and the
25 like, and the accumulation sites thereof are Collins body (intraneuronal). The aggregation or accumulation of ABri peptide is considered to cause diseases such as familial British dementia and the like, and the accumulation site thereof is cerebrovascular amyloid.

30 In the present invention, being in an "equilibrium state" means that the rate of dissolution of soluble peptide, soluble oligopeptide, soluble polypeptide or soluble protein from insoluble fibril or aggregate of peptide, oligopeptide, polypeptide or protein into a solvent is the same as the rate

of aggregation of soluble peptide, oligopeptide, polypeptide or protein in the solvent to form insoluble fibril or aggregate; and they are balanced.

The step of the identification method of the present invention may include simply measuring, in the presence of a test compound, the concentration of soluble peptide, soluble oligopeptide, soluble polypeptide or soluble protein dissolved from fibril or aggregate in a solvent.

In the present invention, by the fibril is meant a structure of about 1 μm in diameter where peptide and the like are linearly linked, and the aggregate means an assemblage of plural fibrils. The fibril and aggregate may be formed *in vitro* or *in vivo*. In consideration of the efficiency, operability, reproducibility of the test and the like of identification of a drug candidate, however, the fibril and aggregate formed *in vitro* is preferable.

In the present invention, by "being removed" means removal of soluble peptide, oligopeptide, polypeptide or protein from fibril or aggregate of aggregated peptide, oligopeptide, polypeptide or protein by dissolution.

For preparation of a sample in an equilibrium state, for example, soluble peptide, oligopeptide, polypeptide or protein, or fibril or aggregate thereof is added to a solvent and stood at an appropriate temperature (generally 0-40°C) until the equilibrium state is achieved. Arrival at the equilibrium state can be confirmed by measuring the concentration of soluble peptide, oligopeptide, polypeptide or protein in a solvent chronologically. When the equilibrium state is achieved, a test compound is added to the reaction system and the mixture is incubated at an appropriate temperature (generally about 37°C) (preferably for 1 day). After centrifugation at an appropriate temperature (generally 0-40°C) for 1-60 min, the obtained supernatant is subjected to an analysis.

For preparation of a sample in a non-equilibrium state, for example, peptide, oligopeptide, polypeptide or protein is added to a solvent, and the mixture is incubated at a suitable temperature (generally 0-40°C) for 1-6 hr to allow
5 fibrillization or aggregation. When the fibrillization or aggregation is completed, the supernatant is separated by centrifugation at an appropriate temperature (generally 0-40°C) for 1-60 min and the like. Then, a test compound is added to the obtained supernatant, and the mixture is incubated at a
10 suitable temperature (generally about 37°C) preferably for one day. After centrifugation at an appropriate temperature (generally 0-40°C) for 1-60 min, the supernatant is collected and subjected to an analysis.

The solvent to be used here for the method of the present
15 invention is not particularly limited as long as it does not prevent the object of the present invention and, for example, buffers such as PBS, acetate buffer, citrate buffer, Tris-HCl buffer and the like are used. The solvent is preferably adjusted to about pH3-8, more preferably about pH6-8 from the
20 aspect of physiological conditions.

The concentration of soluble peptide, oligopeptide, polypeptide or protein in a solvent can be measured by a method known per se. For example, it can be measured by methods such as ELISA, Western blot, mass analysis, size-
25 exclusion chromatography (SEC) and the like.

When, as a result of the above-mentioned measurement, an increase in the concentration of soluble peptide, oligopeptide, polypeptide or protein in a solvent can be confirmed by the addition of the test compound, as compared to
30 the absence of the test compound, the test compound can be determined to be a drug candidate capable of removing peptide, oligopeptide, polypeptide or protein from fibril or aggregate. The thus-obtained compound can be used for various purposes and useful for the development of, for example, a drug for the

prophylaxis or treatment of a disease caused by the aggregation of peptide, oligopeptide, polypeptide or protein or a reagent for studying the disease. As such disease, for example, Alzheimer's disease (AD), Parkinson's syndrome (PD),
5 Huntington chorea, prion disease, Down's syndrome, Lewy body dementia, multiple system atrophy, Creutzfeldt-Jakob disease, Gerstmann-Sträussler syndrome, mad cow disease, spinobulbar muscular atrophy, spinocerebellar ataxia (SCA), dentatorubral-pallidoluysian atrophy (DRPLA), familial amyotrophic lateral
10 sclerosis retinitis, FTDP-17, progressive supranuclear palsy, corticobasal degeneration, Pick disease, familial British dementia or familial dementia accompanying neuroserpin inclusion bodies and the like can be mentioned. According to the present invention, a compound obtained by the
15 identification method of the present invention is also provided.

According to the identification method of the present invention, a drug candidate capable of specifically removing peptide, oligopeptide, polypeptide or protein from fibril or
20 aggregate of particular peptide, oligopeptide, polypeptide or protein can be obtained by appropriately selecting the kind of peptide, oligopeptide, polypeptide or protein. Such drug candidate can be useful for the prophylaxis or treatment of a disease caused by the aggregation of the particular peptide,
25 oligopeptide, polypeptide or protein.

<Ultrasonication>

The above-mentioned equilibrium state may be achieved under ultrasonication. Preferably, the ultrasonication does not substantially accompany heat generation. While the
30 ultrasonication is not particularly limited, generally, 15 repeats of a 10 second ultrasonication under the conditions of 1-20 MHz, 0.1-10 W/cm², duty ratio 10-90% with a 10 second pause are performed, more preferably, 5 repeats of a 30 second ultrasonication under the conditions of 2.5-7.5 MHz, 0.5-5

W/cm², duty ratio 20-70% with a 10 second pause are performed, wherein the duty ratio means transmission time/(transmission time + transmission interval).

The above-mentioned ultrasonication promotes removal of peptide, oligopeptide, polypeptide or protein from fibril or aggregate. Therefore, ultrasonication accelerates arrival at the equilibrium state, and enables more rapid identification of a drug candidate.

Moreover, a method of removing peptide, oligopeptide, polypeptide or protein from fibril or aggregate by ultrasonication is also encompassed in the present invention.

Furthermore, the present invention encompasses a method for the treatment of a disease caused by aggregation of peptide, oligopeptide, polypeptide or protein, which comprises application of ultrasonication to a patient.

The present invention moreover provides an apparatus for treating a disease caused by the aggregation of peptide, oligopeptide, polypeptide or protein, which comprises a means for ultrasonication an affected part to remove peptide, oligopeptide, polypeptide or protein from fibril or aggregate.

For ultrasonication here, generally, 15 repeats of a 10 second ultrasonication under the conditions of 1-20 MHz, 0.1-10 W/cm², duty ratio 10-90% with a 10 second pause are performed, more preferably, 5 repeats of a 30 second ultrasonication under the conditions of 2.5-7.5 MHz, 0.5-5 W/cm², duty ratio 20-70% with a 10 second pause are performed.

<Dissolution promoter>


The present invention provides a dissolution promoter for removing peptide, oligopeptide, polypeptide or protein from fibril or aggregate, which contains, as an active ingredient, a compound obtained by the above-mentioned identification method.

As is clear from the following Examples, as a compound obtained by the above-mentioned identification method, ferric

dehydroporphyrin IX, amphotericin B, myricetin, tannic acid, curcumin, azure B and basic blue 41 are used.

Accordingly, the present invention provides a dissolution promoter for removing peptide, oligopeptide, polypeptide or
5 protein from fibril or aggregate, which contains, as an active ingredient, at least one selected from ferric dehydroporphyrin IX, amphotericin B, myricetin, tannic acid, curcumin, azure B and basic blue 41.


Ferric dehydroporphyrin IX is a compound represented by
10 the following chemical formula 1:



(chemical formula 1)

, which is reported to inhibit *in vitro* the formation of a protease-resistant protein (PrP-res) and to be possibly useful
15 for the treatment of transmissible spongiform encephalopathy (S.A. Priola et al., Science, 287, 1503 (Feb 25, 2000)). There is also a report that the compound inhibits tau filament formation (S. Taniguchi et al., J Biol Chem, 280(9), 7614-7623, 2005).


20 Amphotericin B is a compound represented by the following chemical formula 2:



(chemical formula 2)

, which is known to delay A β fiber formation (S.C. Hartsel et al., Biochemistry 42, 6228 (May 27, 2003)).


15 Myricetin and tannic acid are each a compound represented by the following chemical formulas 3 and 4, respectively:



(chemical formula 3)

25


Chiral



(chemical formula 4)

15 , which have been reported to show *in vitro* inhibitory action on the formation or elongation of A β (K. Ono, *Biochim Biophys Acta* 1690, 193 (Nov 5, 2004)).

Curcumin is a compound represented by the following chemical formula 5:




25 (chemical formula 5)

, which has been reported to inhibit the formation of an A β (1-40) fiber (F. Yang et al., *J Biol Chem*, 280(7), 5892-5901, 2005), and is known to be effective as a therapeutic drug for Alzheimer (G.P. Lim et al., *J Neurosci*, 21(21):8370-7 (Nov 1, 30 2001) and WO03/103583).

Azure B is a compound represented by the following chemical formula 6:


Cl⁻



(chemical formula 6)

, which has been reported to inhibit tau filament formation (S. Taniguchi et al., J Biol Chem 280(9), 7614-7623, 2005).

10 Basic blue 41 is a compound represented by the following chemical formula 7:



20 (chemical formula 7)

, which is one kind of thioflavine T, and thioflavine T is known to be a fluorescence indicator of amyloid fibers (H. Nakai et al, Lab Invest 62, 768 (Jun 1990)).

25 Since the dissolution promoter of the present invention can enhance the action to remove peptide, oligopeptide, polypeptide or protein from fibril or aggregate, it is useful for the prophylaxis or treatment of a disease caused by the aggregation of peptide, oligopeptide, polypeptide or protein.

30 As described in the aforementioned publications, the above-mentioned compounds are all known to be usable for various diseases. Since the compounds were newly found to be able to dissolve peptide, oligopeptide, polypeptide or protein from fibril or aggregate in the present invention, it is suggested that dissolution promoters containing these

compounds can be used for the prophylaxis or treatment of diseases caused by the aggregation of peptide, oligopeptide, polypeptide or protein.

The dissolution promoter of the present invention can
5 contain, in addition to the above-mentioned compound, optional carrier and the like. As the optional carrier, pharmaceutically acceptable carrier (mentioned later) can be mentioned.

The dissolution promoter of the present invention can be
10 used as a pharmaceutical agent or a test reagent and the like, or used *in vivo* or *in vitro*. When the dissolution promoter of the present invention is used as a pharmaceutical agent, it can be orally or parenterally administered to animals (e.g., mammals such as human, simian, bovine, horse, dog, cat,
15 rabbit, rat, mouse and the like), and can be used in the dosage form of oral administration agents such as tablet, capsule, troche, granule, powder and the like or in the dosage form of external preparations (liquid, lotion, suspension, emulsion, cream, ointment, gel etc.), injection, suppository
20 and the like.

As a pharmaceutically acceptable carrier, for example, excipients such as sucrose, starch, mannitol, sorbitol, lactose, glucose, cellulose, talc, calcium phosphate, calcium carbonate and the like, binders such as cellulose, methylcellulose,
25 hydroxypropylcellulose, polypropylpyrrolidone, gelatin, gum arabic, polyethylene glycol, sucrose, starch and the like, disintegrants such as starch, carboxymethylcellulose, hydroxypropyl starch, sodium glycol starch, sodium hydrogencarbonate, calcium phosphate, calcium citrate and the
30 like, lubricants such as magnesium stearate, aerosil, talc, sodium lauryl sulfate and the like, aromatic such as citric acid, menthol, ammonium glycyrrhizinate, glycine, orange powder and the like, preservatives such as sodium benzoate, sodium bisulfite, methylparaben, propylparaben and the like,

stabilizers such as citric acid, sodium citrate, acetic acid and the like, suspending agents such as methylcellulose, polyvinylpyrrolidone, aluminum stearate and the like, diluents such as surfactant and the like, dispersing agent, water, 5 saline, orange juice and the like, base wax such as cacao butter, polyethylene glycol, white kerosene and the like, and the like can be mentioned, though not limited to these.

The preparation preferable for oral administration includes liquids obtained by dissolving an effective amount of 10 a substance in a diluting solution such as water, saline and orange juice, capsule containing an effective amount of a substance as solid or granule, sachet or tablet, suspension wherein an effective amount of a substance is suspended in a suitable dispersion, an emulsion wherein a solution containing 15 an effective amount of a substance is dispersed and emulsified in a suitable dispersion medium and the like.

As a preparation preferable for parenteral administration (e.g., subcutaneous injection, muscular injection, topical injection, intraperitoneal administration and the like), 20 aqueous and non-aqueous isotonic sterile injections can be mentioned, which may contain antioxidant, buffer, antibacterial agent, isotonicity agent and the like. In addition, aqueous and non-aqueous sterile suspensions can be mentioned, which may include suspension, solubilizer, 25 thickener, stabilizer, preservative and the like. The preparation can be sealed in a container by a unit dose or plural doses like ampoules and vials. In addition, an active ingredient and a pharmaceutically acceptable carrier may be lyophilized and preserved such that they only need to be 30 dissolved or dispersed in a suitable sterile vehicle immediately before use.

While the dose of the dissolution promoter of the present invention cannot be said in general, since it varies depending on the activity and kind of the active ingredient, severity of

the disease, the animal species to be the subject of administration, and drug acceptability, body weight, age and the like of the subject of administration, it is generally about 0.001 - about 5 mg/kg/day for an adult based on the
5 amount of the active ingredient.

Examples

The present invention is explained in detail in the following by referring to Examples, which are not to be construed as limitative.

10 Example 1

(I) Method

(1) Reagent and solvent

Unless otherwise specified, the drug was obtained from Sigma Ltd. or Wako.

15 Water was distilled twice, and deionized using a Milli-Q system (Millipore Corporation, Bedford, Massachusetts).

(2) Peptide

A β (1-40) and A β (1-42) were obtained from PEPTIDE INSTITUTE, INC. (Osaka, Japan). A β solution was prepared anew
20 as described in Hartley, Walsh et al. 1999, for every experiment. A β (1-40) peptide (0.55 mg) was dissolved in 1 mM NaOH (130 μ l) containing 0.01% phenol red.

10 mM NaOH was added to adjust the solution to pH 7.5. To give a 500 μ M A β solution, PBS/ddH₂O was added. Undissolved
25 A β was removed by centrifugation before separating the supernatant (15,000 \times g, 3 min).

(3) Sample preparation

The 500 μ M A β solution (20 μ l) was taken in a 1.5 ml Eppendorf tube. The sample was incubated at 37°C for several
30 time periods until completion of fibrillization. After centrifugation at 22°C (15,000 \times g, 10 min), the supernatant was removed.

The obtained pellets (i.e., A β fibril) were washed 3 times with phosphate buffer (PBS). Fresh PBS (20 μ l) was

carefully and gradually added to the pellets. The sample was incubated at 37°C for one day. After centrifugation at 22°C (15,000×g, 10 min), the supernatant (16 µl) was taken and subjected to the analysis. The remaining supernatant was
5 removed. Fresh PBS (20 µl) was carefully and gradually added to the pellets.

The above operation was repeated (see Fig. 1).

The sample was analyzed as in the following by ELISA, Western blot, mass analysis and size-exclusion chromatography
10 (SEC).

(4) Sandwich method Aβ ELISA

Sandwich ELISA for Aβ (1-40) and Aβ (1-42) was performed using an Aβ (1-40) ELISA kit and Aβ (1-42) ELISA kit (Biosoure, IBL, Signet Laboratories and the like).

15 (5) SEC

Superose 6 column (Amersham) was set to the HPLC system consisting of an injector and UV detector. After elution from the column at 0.04 ml/min, peptide was detected by UV absorption at 218 nm.

20 Each experiment was performed at least twice. Prepacked column was washed with 2N NaOH between experiments.

For respective studies, an appropriate column was equilibrated with an elution buffer in an amount corresponding to at least 3-fold column volume, and then calibrated with 5
25 kinds of molecular weight standard product: chicken ovalbumin (44,000); horse myoglobin (17,000); human γ-globulin (158,000); bovine siloglobulin (670,000); and vitamin B₁₂ (1,350).

As the elution buffer, 75 mM NaCl, 5 mM Tris-HCl (pH 7.4)
30 were used.

(6) Gel electrophoresis and Western blot

Using Tris/Tricine gel (Invitrogen), SDS polyacrylamide gel electrophoresis (SDS-PAGE) was performed. A sample was mixed with a 2×SDS sample buffer (Invitrogen), and rapidly

boiled for 5 min prior to electrophoresis. The sample was transferred onto a polyvinylidene difluoride (PVDF) membrane (Millipore Corporation, Bedford, Massachusetts, US).

Western blot was performed using 6E10 antibody.

5 ECL was used as the detection system.

(7) Mass analysis

Analysis of A β species by combined immunoprecipitation/matrix associated laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry
10 (IP/MS) was performed as described (Okochi, Steiner et al. 2002).

(8) Ultrasonication

A sample tube was exposed to ultrasonication (2.5 W/cm²) at room temperature for 30 seconds (5 repeats of 30 sec
15 ultrasonication).

(II) Results

Soluble A β dissolved from aggregated A β .

(1) Sandwich ELISA for dissolved A β (1-40) and A β (1-42)

Sandwich ELISA for dissolved A β (1-40) and A β (1-42) was
20 performed according to the described experiment method. The amount of the dissolved A β (1-40) was 6562.5 \pm 1750.9 (S.E.) pg/ml (n=6). The amount of the dissolved A β (1-42) was 1939.7 \pm 607.6 (S.E.) pg/ml (n=6). The respective results are shown in Fig. 2.

25 (2) Mass analysis of dissolved A β (1-40) and A β (1-42)

The molecular weight of dissolved A β (1-40) and A β (1-40) was confirmed to be 4329.8 and 4514.0, respectively, by mass analysis (Fig. 3).

(3) Western blot of dissolved A β (1-40)

30 Detection of a nearly single band of low molecular weight is shown (Fig. 4).

(4) SEC analysis of dissolved A β (1-40) and A β (1-42)

SEC analysis showed a sufficient single 2.4 ml peak (Fig. 5).

(5) Effect of ultrasonication

Ultrasonication promoted A β dissolution.

A sample tube was exposed to ultrasonication (2.5 W/cm²) at room temperature, duty ratio 20% for 30 seconds (5 repeats
5 of 30 sec ultrasonication).

Sandwich ELISA for dissolved A β (1-40) and A β (1-42) was performed.

Ultrasonication for 30 seconds (5 repeats of 30 second ultrasonication at 2.5 W/cm², duty ratio 20%, room temperature)
10 promoted dissolution of A β (1-40) (Fig. 6).

(control group: 8791.7 \pm 3121.1 (S.E.) pg/ml (n=3);
ultrasonication group: 49479.3 \pm 2167.6 (S.E.) pg/ml (n=3); less
than p 0.001)

In another experiment method at duty ratio 50% (30
15 seconds, 2.5 W/cm², room temperature, 2 repeats of 30 second ultrasonication), dissolution of A β (1-40) was promoted.

(control group: 8791.7 \pm 3121.1 (S.E.) pg/ml (n=3);
ultrasonication group 50% \times twice: 35520 \pm 7140 (S.E.) pg/ml
(n=3); p less than 0.05)

20 The effect of ultrasonication is shown in Fig. 7.

(6) SEC analysis of A β (1-42) fibrillization and oligomerization

After dissolution, soluble A β (1-42) was immediately subjected to Superose 6 chromatography analysis by the
25 experiment method as described. The results are shown in Fig. 8.

A peak derived from the gel (gel-included peak) was eluted at 1.9 ml.

The A β oligomer size in the peak could not be determined.

30 A large oligomer and a fibril precursor were observed during the time between 1 h and 12 h (arrow or triangle in the Figure).

The peak at 2.4 m increased at 5 h (arrow in the Figure).

Since this peak was observed when the dissolution of A β

(1-40) was analyzed by SEC, it was eluted in the same fraction.

Example 2

5 (I) Method

(1) Reagent and solvent

Ferric dehydroporphyrin IX, amphotericin B, myricetin, tannic acid, curcumin, azure B and basic blue 41 were each obtained from Sigma-Aldrich.

10 Except those mentioned above, the preparation followed Example 1.

(2) Peptide

Peptide was prepared in the same manner as in Example 1, (I) - (2).

15 (3) Sample preparation

A 500 μ M A β (1-42) solution (20 μ l) was separated in a 1.5 ml tube. The peptide was incubated for several days at 37°C until fibrillization was completed. After centrifugation at 22°C (15,000 \times g, 10 min), the supernatant was removed. The
20 obtained pellets were gradually and carefully washed 3 times with PBS. Fresh PBS (20 μ l) was carefully and gradually added to the pellets. The sample was incubated at 37°C for one day. After centrifugation (15,000 \times g, 10 min) at 22°C, the supernatant was removed. Then, fresh PBS (20 μ l) containing a
25 compound: ferric dehydroporphyrin IX, amphotericin B, myricetin, tannic acid, curcumin, azure B or basic blue 41, or fresh PBS (20 μ l) without any compounds as a control were carefully and gradually added to the pellets. The sample was incubated at 37°C for one day. After centrifugation (15,000 \times g,
30 10 min) at 22°C, the supernatant (16 μ l) (A β dissolved from fibril) was taken and subjected to A β ELISA analysis.

(II) Results

The results are shown in Table 1 and Fig. 10.

Table 1

	average	SE
ferric dehydroporphyrin IX	1.4124	0.224152
amphotericin B	1.5309	0.161446
myricetin	1.3196	0.16005
tannic acid	1.3969	0.123811
curcumin	2.4691	0.282381
azure B	2.1701	0.044954
basic blue 41	2.299	0.220559
control	1	0.303872

The average value shows the ratio when the control is 1.

As shown in Table 1 and Fig. 10, when the above-mentioned compound was added, significant dissolution of A β was observed.

5

References

1. DeMattos, R. B., K. R. Bales, et al. (2001).
 "Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model
 10 of Alzheimer's disease."
 Proc Natl Acad Sci U S A 98(15): 8850-5.
2. Hartley, D. M., D. M. Walsh, et al. (1999).
 "Protofibrillar intermediates of amyloid beta-protein induce
 acute electrophysiological changes and progressive
 15 neurotoxicity in cortical neurons."
 J Neurosci 19(20): 8876-84.
3. Lombardo, J. A., E. A. Stern, et al. (2003).
 "Amyloid-beta antibody treatment leads to rapid normalization
 of plaque-induced neuritic alterations."
 20 J Neurosci 23(34): 10879-83.
4. Matsuoka, Y., M. Saito, et al. (2003).
 "Novel therapeutic approach for the treatment of Alzheimer's
 disease by peripheral administration of agents with an
 affinity to beta-amyloid."
 25 J Neurosci 23(1): 29-33.

5. Okochi, M., H. Steiner, et al. (2002).

"Presenilins mediate a dual intramembranous gamma-secretase cleavage of Notch-1."

Embo J 21(20): 5408-16.

5 6. Schenk, D., R. Barbour, et al. (1999).

"Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse."

Nature 400(6740): 173-7.

10

Industrial Applicability

As is clear from the foregoing explanation, the present invention enables identification of a drug candidate capable of removing peptide, oligopeptide, polypeptide or protein from fibril or aggregate, by which the present invention is

15 expected to be highly useful for the treatment, prophylaxis or study of the diseases caused by the aggregation of peptide, oligopeptide, polypeptide or protein, such as Alzheimer's disease and the like, which have various repercussions in the modern society.

20

This application is based on a patent application No. 2004-107746 filed in Japan, the contents of which are incorporated in full herein by this reference.

25

Sequence Listing Free Text

SEQ ID NO: 1: A β (1-40)

SEQ ID NO: 2: A β (1-42)